Biovitrum AB and Syntonix Pharmaceuticals, Inc., today announced that the company's FIXFc compound for the control and prevention of hemorrhagic episodes in patients with hemophilia B has received an orphan-drug designation from the US FDA.
The details can be read here.
No comments:
Post a Comment